1[2]Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994;74:1-23
2[3]Chari S. Hirudin-based synthetic peptides as inhibitors of thrombin. Semin Thromb Hemost 1994;20:315-8
3[4]Johnson PH. Hirudin: clinical potential of a thrombin inhibitor.Ann Rev Med 1994;45:165-77
4[5]Giancarlo Agnelli, Francesco Sonaglia. Prevention of venous thromboembolism. Thromb Res. 2000 Jan 1; (97) :V49-62
5[6]Investigator's Brochure HBW 023 (lepirudin). Behringwerke AG,Clinical Research Thrombosis. Edition Number 6:1996
6[7]Eriksson BI, Ekman S, K～llebo P, et al. Prevention of deepvein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996;347:635-9
7[8]Parent F, Bridey F, Dreyfuls M, et al. Treatment of severe venous thromboembolism with intravenous hirudin (HBW 023): an open pilot study. Thromb Haemost 1993;70:386-8
8[9]Schiele F, Vuillemenot A, Kramarz P, et al. A pilot study of subcutaneous recombinant hirudin (HBW 023 ) in the treatment of deep vein thrombosis, Thromb Haemost 1994;71:558-62
9[10]B. I. Eriksson. New therapeutic options in deep vein thrombosis prophvlaxis. Semin Hematol. 2000 Jul; 37(3 suppl 5) : 7-9
